These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 18784373

  • 1. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
    Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T.
    Blood; 2008 Nov 15; 112(10):3959-64. PubMed ID: 18784373
    [Abstract] [Full Text] [Related]

  • 2. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
    Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, De Agustin JJ, Fuente D, Corominas H, Sanmarti R, Zamora C, Cantó E, Vidal S.
    Semin Arthritis Rheum; 2018 Jun 15; 47(6):757-764. PubMed ID: 29157669
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
    Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y.
    Int Immunopharmacol; 2005 Nov 15; 5(12):1731-40. PubMed ID: 16102523
    [Abstract] [Full Text] [Related]

  • 5. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
    Robak T, Gladalska A, Stepień H, Robak E.
    Mediators Inflamm; 1998 Nov 15; 7(5):347-53. PubMed ID: 9883970
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
    Hashizume M, Mihara M.
    Rheumatol Int; 2009 Feb 15; 29(4):397-401. PubMed ID: 18802703
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.
    Zhang X, Georgy A, Rowell L.
    Int J Clin Pharmacol Ther; 2013 Jun 15; 51(6):443-55. PubMed ID: 23547848
    [Abstract] [Full Text] [Related]

  • 9. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
    Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L, Hemeryck A, Jacobs S, Baumeister J, Ulrichts H.
    Arthritis Res Ther; 2015 May 20; 17(1):135. PubMed ID: 25994180
    [Abstract] [Full Text] [Related]

  • 10. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
    Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, Grupp SA, June CH, Melenhorst JJ, Lacey SF.
    J Immunol Methods; 2016 Jul 20; 434():1-8. PubMed ID: 27049586
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
    Peake NJ, Khawaja K, Myers A, Nowell MA, Jones SA, Rowan AD, Cawston TE, Foster HE.
    Rheumatology (Oxford); 2006 Dec 20; 45(12):1485-9. PubMed ID: 16690760
    [Abstract] [Full Text] [Related]

  • 15. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N, Kishimoto T.
    Handb Exp Pharmacol; 2008 Dec 20; (181):151-60. PubMed ID: 18071945
    [Abstract] [Full Text] [Related]

  • 16. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
    Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, Ahmadian MR, Moll JM, Scheller J.
    J Biol Chem; 2018 May 04; 293(18):6762-6775. PubMed ID: 29559558
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
    Cronstein BN.
    Bull NYU Hosp Jt Dis; 2007 May 04; 65 Suppl 1():S11-5. PubMed ID: 17708739
    [Abstract] [Full Text] [Related]

  • 18. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production.
    Uchiyama Y, Yoshida H, Koike N, Hayakawa N, Sugita A, Nishimura T, Mihara M.
    Int Immunopharmacol; 2008 Nov 04; 8(11):1595-601. PubMed ID: 18664393
    [Abstract] [Full Text] [Related]

  • 19. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
    Hashizume M, Hayakawa N, Mihara M.
    Rheumatology (Oxford); 2008 Nov 04; 47(11):1635-40. PubMed ID: 18786965
    [Abstract] [Full Text] [Related]

  • 20. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis.
    Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M.
    Biol Pharm Bull; 2008 Jun 04; 31(6):1159-63. PubMed ID: 18520048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.